Gaudium IVF and Women Health Ltd (GAUDIUMIVF) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company marked a defining year by becoming the country's first IVF company to be listed on the main boards, successfully raising approximately INR 165 crores through its IPO in February 2026.
- Gaudium IVF demonstrated strong financial performance in Q4 FY26, with significant growth in revenue, EBITDA, and PAT, driven by high volumes at mature hubs and growing demand for fertility treatments.
- The company is aggressively pursuing a capital-efficient expansion strategy, with plans to open 19 new hubs and associated spokes, funded by IPO proceeds and internal accruals, aiming to deepen its presence in Tier-2 markets and reinforce metro hubs.
- A key strategic milestone was the formal integration of AI-led embryology tools (Sid and Erica) into clinical practice, a first in India, which is expected to increase success rates at the first attempt and improve operational efficiency.
- The company is strengthening its focus on medical tourism, which currently contributes 25-30% of revenue, by opening three new international spokes in Nigeria, Sydney, and Paris to capitalize on the significant cost advantage of IVF treatments in India.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.